PURPOSE: Mucosa-associated lymphoid tissue (MALT) @entity706 is a distinct disease with specific clinical and pathologic features that may affect diverse organs. We analyzed our recent experience with Stage I/II @entity1074 presenting in the stomach and other organs to assess the outcome following involved field @entity1161 ( @entity1161 ). @entity1 AND METHODS: Seventy @entity1 with Stage IE (62) and IIE (8) disease were treated between 1989 and 1998. @entity1 with transformed MALT were excluded. The median age was 62 years (range, 24--83 years), M:F ratio 1:2.2. Presenting sites included stomach, 15; orbital adnexa, 19; salivary glands, 15; thyroid, 8; lung, 5; upper airways, 3 (nasopharynx, 2; larynx, 1); urinary bladder, 3; breast, 1; and rectum, 1. Staging included site-specific imaging, CT abdomen in 66 @entity1 (94%) and bone marrow biopsy in 54 (77%). Sixty-two @entity1 received @entity1161 : 52 received @entity1161 alone, 7 received chemotherapy and @entity1161 , and 3 received antibiotics followed by @entity1161 . Median @entity1161 dose was 30 Gy (range, 17.5--35 Gy). Most frequently used @entity1161 prescriptions were 25 Gy (26 @entity1 -18 orbit, 6 stomach, and 2 salivary glands), 30 Gy (23 @entity1 ), and 35 Gy (8 @entity1 ). Five @entity1 had complete surgical excision of @entity706 and no other treatment (stomach 1, salivary 2, lung 2), whereas 2 @entity1 with @entity6595 received antibiotics only. One @entity1 refused treatment and was excluded from the analysis of treatment outcome, leaving 69 @entity1 with a median follow-up of 4.2 years (range, 0.3-11.4 years). RESULTS: A complete response was achieved in 66/69 @entity1 , and 3 @entity1 had partial response (2 lung, 1 orbit). The 5-year disease-free survival (DFS) was 76%, and the overall survival was 96%. No relapses were observed in @entity1 with stomach and @entity706 . The 5-year DFS for these @entity1 was 93%, in contrast to 69% for @entity1 presenting in other sites (p = 0.006). Among the 5 @entity1 treated with surgery only, 2 relapsed locally (lung, and minor salivary gland). Among 62 @entity1 who received @entity1161 , 8 relapsed (2 salivary, 3 orbit, 1 nasopharynx, 1 larynx, 1 breast). Three @entity1 relapsed in the nonirradiated contralateral paired organ, 4 in distant sites, and 1 in both local and distant sites. The overall local control rate with radiation was 97% (60/62 @entity1 ). CONCLUSION: Localized @entity1074 have excellent prognosis following moderate-dose @entity1161 . Gastric and thyroid @entity1074 have better early outcome, as compared to the other sites where distant failure is more common. Relapses were observed in nonirradiated paired organs or distant sites. Further follow-up is required to assess the impact of failure on survival.

Stage I and II XXXX : results of treatment with radiotherapy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma', 'thyroid lymphoma'] @entity6595 :: ('MESH:C535648', 'Disease') :: ['gastric lymphoma'] @entity1161 :: ('MESH:D011832', 'Disease') :: ['radiation therapy', 'RT'] @entity1074 :: ('MESH:D018442', 'Disease') :: ['MALT lymphoma', 'MALT lymphomas']
@entity1074 :: (MESH:D018442,Disease) :: ['MALT lymphoma']
